Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus LODINE XL.
ADVIL LIQUI-GELS vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
400 mg or 600 mg orally once daily.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID